Socioeconomic position and the gut microbiota: a narrative synthesis of the association and recommendations.

Gut MicrobesJan 31, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Jasmine Samantha Ratcliff, Meena Kumari, Patrick Varga-Weisz et al.

✦ AI-curated · Sources linked

In 30 seconds

This narrative systematic review synthesised observational studies of socioeconomic position (SEP) and gut microbiota (GM) diversity, composition, or function across participants of any age and location. Of 1,479 unique studies identified, 26 met the inclusion criteria. SEP indicators were associated with multiple GM features, but patterns varied by context: alpha diversity was greater in advantaged groups in high-income countries and in disadvantaged groups in low- and middle-income countries. Beta-diversity findings also indicated distinct GM profiles across socioeconomic groups. The authors noted substantial methodological heterogeneity and called for stronger studies to clarify these relationships.

Key findings

  • Of 1,479 unique studies identified, 26 observational studies met the review’s inclusion criteria.
  • Alpha diversity was greater in advantaged groups in high-income countries, but in disadvantaged groups in low- and middle-income countries.
  • Beta-diversity differences suggested distinct gut microbiota profiles between advantaged and disadvantaged groups.
  • Studies varied considerably in sampling, sequencing, and analytical methods.

Why it matters

The findings suggest that social and environmental conditions may be associated with gut microbiota differences relevant to health inequalities. The contrasting alpha-diversity patterns across income settings caution against assuming a uniform socioeconomic gradient. Better understanding of these relationships may help assess whether microbiota-related pathways contribute to disparities, although the review does not establish causation.

What to keep in mind

The evidence came from observational studies and was heterogeneous, particularly in sampling, sequencing, and analytical methods. The authors call for larger, more diverse cohorts, longitudinal designs, metagenomic sequencing, and more comprehensive covariate measurement and adjustment.

Source

Published in Gut Microbes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.